- Arena will receive $800M upfront, and is eligible to receive low double-digit tiered royalties, plus up to $400M in milestone payments - United Therapeutics will receive exclusive, worldwide rights to ralinepag - a potential best-in-class agent for the treatment of pulmonary arterial hypertension
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C. , Nov. 1, 2018 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ: UTHR) announced today the appointment of Nilda Mesa to its Board of Directors as an independent director. The appointment is effective as of October 31, 2018 .
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C. , Oct. 31, 2018 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ: UTHR) today announced its financial results for the quarter ended September 30, 2018. "We are pleased to see continued growth in the number of U.S.
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C. , Oct. 24, 2018 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ: UTHR) announced today that it will report its third quarter 2018 financial results before the market opens on Wednesday, October 31, 2018 .
Collaboration Combines CollPlant's Proprietary rhCollagen-based Bioink Technology and United Therapeutics' Regenerative Medicine and Organ Manufacturing Capabilities NESS ZIONA, Israel and SILVER SPRING, Md. , Oct. 22, 2018 /PRNewswire/ -- CollPlant (NASDAQ: CLGN, TASE: CLGN) and United
RESEARCH TRIANGLE PARK, N.C. and WESTLAKE VILLAGE, Calif. , Oct. 16, 2018 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) and MannKind Corporation (Nasdaq: MNKD) today announced the closing of their pending worldwide exclusive license and collaboration agreement for the development
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C. , Sept. 18, 2018 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ: UTHR) announced today that it will host Science Day 2018 in New York City on Monday, September 24 th , beginning at approximately 10:00 A.M.
SAN DIEGO and SILVER SPRING, Md. , Sept. 17, 2018 /PRNewswire/ -- Samumed LLC has entered an exclusive license agreement with United Therapeutics Corporation (Nasdaq: UTHR) for North American rights to Samumed's SM04646, being developed for the treatment of idiopathic pulmonary fibrosis (IPF).
Exclusive license agreement for Treprostinil Technosphere®; $95 million in upfront and milestone payments Research agreement for additional products for additional $10 million SILVER SPRING, Md. and WESTLAKE VILLAGE, Calif. , Sept. 4, 2018 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq:
SILVER SPRING, Md. , Aug. 30, 2018 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ: UTHR) (" United Therapeutics ") today announced that it has closed the merger of SteadyMed Ltd. (NASDAQ: STDY) (" SteadyMed ") with a subsidiary of United Therapeutics .
